行情

CVM

CVM

CEL SCI
AMEX

实时行情|Nasdaq Last Sale

7.91
+0.11
+1.41%
已收盘, 16:22 11/20 EST
开盘
7.80
昨收
7.80
最高
8.25
最低
7.55
成交量
77.26万
成交额
--
52周最高
9.93
52周最低
2.367
市值
2.75亿
市盈率(TTM)
-6.8556
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CVM 新闻

  • CEL-SCI Corporation to Present at Dawson James Securities 5th Annual Small Cap Growth Conference
  • Business Wire.10/29 12:00
  • CEL-SCI down 9% on capital raise doubts
  • Seeking Alpha - Article.10/24 19:35
  • 'Cel-Sci is publicly upbeat about its cancer drug. Privately it's trying to sell stock' -STAT News' Adam Feuerstein
  • Benzinga.10/24 18:17
  • CEL-SCI Corporation Issues Letter to Shareholders
  • Business Wire.10/24 13:00

更多

所属板块

生物技术和医学研究
+0.65%
制药与医学研究
-0.14%

热门股票

名称
价格
涨跌幅

CVM 简况

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.
展开

Webull提供CEL-SCI Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。